SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers

Background: Patients with epithelial ovarian cancer (EOC) receiving neoadjuvant platinum-based chemotherapy (NACT) who remain ineligible for complete interval cytoreductive surgery (ICS) due to poor chemosensitivity (CA-125 KELIM™ score <1.0) have a poor prognosis (~20% 5-year survival). A weekly do...

Полное описание

Библиографические подробности

Главные авторы:	Claire Chator, Nozomu Yanaihara, Sylvie Chabaud, Gabriella Maria Parma, Alexandra L. Dima, Andrew Clamp, Gwenaël Ferron, Judith R. Kroep, Alexandra Leary, David Cibula, Frederic Fiteni, Ilan Bruchim, Hassan Serrier, Susannah Carroll, Anne-Sophie Belmont, Julien Peron, Benoit You
Формат:	Artigo
Язык:	Inglês
Опубликовано:	SAGE Publishing 2025-12-01
Серии:	Therapeutic Advances in Medical Oncology
Online-ссылка:	https://doi.org/10.1177/17588359251396777
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!